ESRP1 and neoplasm: We identified two (according to TvHdb) putative tumor-specific cryptic peptides (RVYLDIVTPK, IFT81 and SSIRSWNNK, ESRP1) with increased presentation after short-term MAPKi treatment in wildtype as well as in resistant cells (Figures 5B, C), indicating that their presentation is not directly linked to MAPK signaling.